{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T18:25:27Z","timestamp":1788805527301,"version":"build-2803163510"},"reference-count":42,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2019,8,4]],"date-time":"2019-08-04T00:00:00Z","timestamp":1564876800000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81573472"],"award-info":[{"award-number":["81573472"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81770004"],"award-info":[{"award-number":["81770004"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"13th Five-Year Plan of National Major Science and Technology Projects of China","award":["2018ZX09201-013"],"award-info":[{"award-number":["2018ZX09201-013"]}]},{"name":"Clinical Research Support Funding of PLA General Hospital","award":["2016FC-TSYS-2043"],"award-info":[{"award-number":["2016FC-TSYS-2043"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Use of tigecycline in treating MDR Acinetobacter baumannii (MDRAB) remains controversial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To comprehensively assess the safety and efficacy of tigecycline in pneumonia caused by Acinetobacter baumannii.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>PubMed, Embase, Web of Science and Cochrane library databases were searched up to 12 March 2019. Studies were included if they compared tigecycline-based regimens with other antibiotic regimens for treating AB pulmonary infections and we pooled the clinical outcomes, microbiological response, adverse events or mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>One prospective study and nine retrospective studies were included in this meta-analysis. The results showed similar clinical cure rates (OR\u205f=\u205f1.04, 95% CI\u205f=\u205f0.60\u20131.81; P\u205f=\u205f0.89) and mortality rates (OR\u205f=\u205f1.11, 95% CI\u205f=\u205f0.65\u20131.89; P\u205f=\u205f0.71) comparing tigecycline groups with the control groups. However, a significantly lower microbiological eradication rate was found in the tigecycline groups (OR\u205f=\u205f0.43, 95% CI\u205f=\u205f0.27\u20130.66; P\u205f=\u205f0.0001). Incidence of nephrotoxicity in tigecycline-based regimens was significantly lower than in colistin-based regimens (OR\u205f=\u205f0.34, 95% CI\u205f=\u205f0.16\u20130.74, I2\u205f=\u205f35%, P\u205f=\u205f0.006). There were no randomized controlled trials (RCTs) included; incomplete safety data and regional bias caused by the majority of the studies originating in China are the main limitations of this meta-analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Tigecycline can be used for treating MDRAB pulmonary infections owing to efficacy similar to that of other antibiotics. Moreover, tigecycline did not show a higher risk of mortality. Considering the lower microbiological eradication rate for tigecycline, which is likely to induce antimicrobial resistance, well-designed RCTs for high-dose tigecycline in treating pneumonia caused by AB are still needed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkz337","type":"journal-article","created":{"date-parts":[[2019,7,24]],"date-time":"2019-07-24T07:25:50Z","timestamp":1563953150000},"page":"3423-3431","source":"Crossref","is-referenced-by-count":36,"title":["Efficacy and safety of tigecycline in treatment of pneumonia caused by MDR Acinetobacter baumannii: a systematic review and meta-analysis"],"prefix":"10.1093","volume":"74","author":[{"given":"Hekun","family":"Mei","sequence":"first","affiliation":[{"name":"Center of Medicine Clinical Research, Department of Pharmacy, PLA General Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianli","family":"Yang","sequence":"additional","affiliation":[{"name":"Center of Medicine Clinical Research, Department of Pharmacy, PLA General Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Wang","sequence":"additional","affiliation":[{"name":"Center of Medicine Clinical Research, Department of Pharmacy, PLA General Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Wang","sequence":"additional","affiliation":[{"name":"Center of Medicine Clinical Research, Department of Pharmacy, PLA General Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6687-9984","authenticated-orcid":false,"given":"Yun","family":"Cai","sequence":"additional","affiliation":[{"name":"Center of Medicine Clinical Research, Department of Pharmacy, PLA General Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,8,3]]},"reference":[{"key":"2019111507201511200_dkz337-B1","doi-asserted-by":"crossref","first-page":"15279.","DOI":"10.1038\/s41598-017-13148-y","article-title":"Bacteremic and non-bacteremic pneumonia caused by Acinetobacter baumannii in ICUs of South China: a clinical and microbiological study","volume":"7","author":"Tan","year":"2017","journal-title":"Sci Rep"},{"key":"2019111507201511200_dkz337-B2","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","article-title":"Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance","volume":"18","author":"Magiorakos","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"2019111507201511200_dkz337-B3","doi-asserted-by":"crossref","first-page":"3277","DOI":"10.1093\/jac\/dkx322","article-title":"High incidence of pandrug-resistant Acinetobacter baumannii isolates collected from patients with ventilator-associated pneumonia in Greece, Italy and Spain as part of the MagicBullet clinical trial","volume":"72","author":"Nowak","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2019111507201511200_dkz337-B4","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/nrd1857","article-title":"Tigecycline","volume":"4","author":"Wenzel","year":"2005","journal-title":"Nat Rev Drug Discov"},{"key":"2019111507201511200_dkz337-B5","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1159\/000118660","article-title":"Baseline in vitro activity of tigecycline among key bacterial pathogens exhibiting multidrug resistance","volume":"54","author":"Draghi","year":"2008","journal-title":"Chemotherapy"},{"key":"2019111507201511200_dkz337-B6","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1093\/jac\/dkq224","article-title":"Successful treatment with tigecycline of two patients with complicated urinary tract infections caused by extended-spectrum \u03b2-lactamase-producing Escherichia coli","volume":"65","author":"Geerlings","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"2019111507201511200_dkz337-B7","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.diagmicrobio.2013.07.014","article-title":"Tigecycline in the management of osteomyelitis: a case series from the bone and joint infection (BAJIO) database","volume":"77","author":"Griffin","year":"2013","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2019111507201511200_dkz337-B8","doi-asserted-by":"crossref","first-page":"e31.","DOI":"10.4081\/idr.2012.e31","article-title":"Successful treatment of Leuconostoc bacteremia in a neutropenic patient with tigecycline","volume":"4","author":"Patel","year":"2012","journal-title":"Infect Dis Rep"},{"key":"2019111507201511200_dkz337-B9","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1089\/mdr.2012.0010","article-title":"Clinical experience of tigecycline treatment in infections caused by extensively drug-resistant Acinetobacter spp","volume":"18","author":"Moon","year":"2012","journal-title":"Microb Drug Resist"},{"key":"2019111507201511200_dkz337-B10","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1093\/jac\/dkr242","article-title":"Efficacy and safety of tigecycline: a systematic review and meta-analysis","volume":"66","author":"Yahav","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"2019111507201511200_dkz337-B11","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/S1473-3099(11)70177-3","article-title":"Efficacy and safety of tigecycline for the treatment of infectious diseases: a meta-analysis","volume":"11","author":"Tasina","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"2019111507201511200_dkz337-B12","year":"2013"},{"key":"2019111507201511200_dkz337-B13","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.2146\/ajhp050487","article-title":"Tigecycline: a new glycylcycline antimicrobial agent","volume":"63","author":"Kasbekar","year":"2006","journal-title":"Am J Health Syst Pharm"},{"key":"2019111507201511200_dkz337-B14","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1164\/rccm.200405-644ST","article-title":"Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia","volume":"171","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"2019111507201511200_dkz337-B15"},{"key":"2019111507201511200_dkz337-B16","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"key":"2019111507201511200_dkz337-B17","author":"Wells"},{"key":"2019111507201511200_dkz337-B18","first-page":"281","article-title":"Guide to clinical preventive services. Report of the US Preventive Services Task Force","volume":"91","author":"Allen","year":"1991","journal-title":"J Am Osteopath Assoc"},{"key":"2019111507201511200_dkz337-B19","doi-asserted-by":"crossref","first-page":"13.","DOI":"10.1186\/1471-2288-5-13","article-title":"Estimating the mean and variance from the median, range, and the size of a sample","volume":"5","author":"Hozo","year":"2005","journal-title":"BMC Med Res Methodol"},{"key":"2019111507201511200_dkz337-B20","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","year":"2011"},{"key":"2019111507201511200_dkz337-B21","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.jmii.2015.06.009","article-title":"Comparison of the clinical efficacy between tigecycline plus extended-infusion imipenem and sulbactam plus imipenem against ventilator-associated pneumonia with pneumonic extensively drug-resistant Acinetobacter baumannii bacteremia, and correlation of clinical efficacy with in vitro synergy tests","volume":"49","author":"Jean","year":"2016","journal-title":"J Microbiol Immunol Infect"},{"key":"2019111507201511200_dkz337-B22","doi-asserted-by":"crossref","first-page":"102.","DOI":"10.1186\/1471-2334-14-102","article-title":"Effectiveness of tigecycline-based versus colistin-based therapy for treatment of pneumonia caused by multidrug-resistant Acinetobacter baumannii in a critical setting: a matched cohort analysis","volume":"14","author":"Chuang","year":"2014","journal-title":"BMC Infect Dis"},{"key":"2019111507201511200_dkz337-B23","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.21037\/jtd.2016.10.29","article-title":"Tigecycline combination for ventilator-associated pneumonia caused by extensive drug-resistant Acinetobacter baumannii","volume":"8","author":"He","year":"2016","journal-title":"J Thorac Dis"},{"key":"2019111507201511200_dkz337-B24","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1007\/s00134-015-4010-z","article-title":"Colistin-tigecycline versus colistin-imipenem-cilastatin combinations for the treatment of Acinetobacter baumannii ventilator-acquired pneumonia: a prognosis study","volume":"41","author":"Chaari","year":"2015","journal-title":"Intensive Care Med"},{"key":"2019111507201511200_dkz337-B25","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.ijantimicag.2014.01.016","article-title":"Colistin-based treatment for extensively drug-resistant Acinetobacter baumannii pneumonia","volume":"43","author":"Khawcharoenporn","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"2019111507201511200_dkz337-B26","doi-asserted-by":"crossref","first-page":"e0150642.","DOI":"10.1371\/journal.pone.0150642","article-title":"Comparable efficacy of tigecycline versus colistin therapy for multidrug-resistant and extensively drug-resistant Acinetobacter baumannii pneumonia in critically ill patients","volume":"11","author":"Kim","year":"2016","journal-title":"PLoS One"},{"key":"2019111507201511200_dkz337-B27","doi-asserted-by":"crossref","first-page":"588","DOI":"10.5414\/CP202557","article-title":"Comparison of the efficacies of three empirically-selected antibiotics for treating Acinetobacter baumannii pulmonary infection: experience from a teaching hospital in China","volume":"55","author":"Li","year":"2017","journal-title":"Int J Clin Pharmacol Ther"},{"key":"2019111507201511200_dkz337-B28","doi-asserted-by":"crossref","first-page":"908.e1","DOI":"10.1016\/j.cmi.2017.10.033","article-title":"Antibiotic strategies and clinical outcomes in critically ill patients with pneumonia caused by carbapenem-resistant Acinetobacter baumannii","volume":"24","author":"Liang","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"2019111507201511200_dkz337-B29","doi-asserted-by":"crossref","first-page":"374.","DOI":"10.1186\/s12879-016-1717-6","article-title":"Tigecycline-based versus sulbactam-based treatment for pneumonia involving multidrug-resistant Acinetobacter calcoaceticus-Acinetobacter baumannii complex","volume":"16","author":"Ye","year":"2016","journal-title":"BMC Infect Dis"},{"key":"2019111507201511200_dkz337-B30","doi-asserted-by":"crossref","first-page":"e12278.","DOI":"10.1097\/MD.0000000000012278","article-title":"Treatment outcomes of patients with non-bacteremic pneumonia caused by extensively drug-resistant Acinetobacter calcoaceticus-Acinetobacter baumannii complex isolates: is there any benefit of adding tigecycline to aerosolized colistimethate sodium?","volume":"97","author":"Jean","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"2019111507201511200_dkz337-B31","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ijantimicag.2015.11.011","article-title":"Tigecycline treatment experience against multidrug-resistant Acinetobacter baumannii infections: a systematic review and meta-analysis","volume":"47","author":"Ni","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"2019111507201511200_dkz337-B32","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1093\/jac\/dkx368","article-title":"Comparative efficacy and safety of treatment options for MDR and XDR Acinetobacter baumannii infections: a systematic review and network meta-analysis","volume":"73","author":"Kengkla","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2019111507201511200_dkz337-B33","doi-asserted-by":"crossref","first-page":"7263","DOI":"10.1128\/AAC.01275-16","article-title":"A novel genome-editing platform for drug-resistant Acinetobacter baumannii reveals an AdeR-unrelated tigecycline resistance mechanism","volume":"60","author":"Trebosc","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2019111507201511200_dkz337-B34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejps.2019.02.023","article-title":"Combating tigecycline resistant Acinetobacter baumannii: a leap forward towards multi-epitope based vaccine discovery","volume":"132","author":"Ahmad","year":"2019","journal-title":"Eur J Pharm Sci"},{"key":"2019111507201511200_dkz337-B35","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ijantimicag.2012.09.005","article-title":"The emergence of clinical resistance to tigecycline","volume":"41","author":"Sun","year":"2013","journal-title":"Int J Antimicrob Agents"},{"key":"2019111507201511200_dkz337-B36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijantimicag.2014.01.006","article-title":"Effectiveness and safety of high-dose tigecycline-containing regimens for the treatment of severe bacterial infections","volume":"44","author":"Falagas","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"2019111507201511200_dkz337-B37","doi-asserted-by":"crossref","first-page":"e12467.","DOI":"10.1097\/MD.0000000000012467","article-title":"Adverse events of high-dose tigecycline in the treatment of ventilator-associated pneumonia due to multidrug-resistant pathogens","volume":"97","author":"Chen","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"2019111507201511200_dkz337-B38","doi-asserted-by":"crossref","first-page":"R90.","DOI":"10.1186\/cc13858","article-title":"High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria","volume":"18","author":"De Pascale","year":"2014","journal-title":"Crit Care"},{"key":"2019111507201511200_dkz337-B39","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1128\/AAC.01232-12","article-title":"Randomized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipenem-cilastatin for treatment of hospital-acquired pneumonia","volume":"57","author":"Ramirez","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2019111507201511200_dkz337-B40","doi-asserted-by":"crossref","first-page":"4658","DOI":"10.1128\/AAC.49.11.4658-4666.2005","article-title":"Safety and efficacy of tigecycline in treatment of skin and skin structure infections: results of a double-blind phase 3 comparison study with vancomycin-aztreonam","volume":"49","author":"Breedt","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"2019111507201511200_dkz337-B41","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1016\/j.jcf.2015.07.008","article-title":"Tigecycline-induced acute pancreatitis in a cystic fibrosis patient: a case report and literature review","volume":"15","author":"Hemphill","year":"2016","journal-title":"J Cyst Fibros"},{"key":"2019111507201511200_dkz337-B42","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1128\/AAC.04305-14","article-title":"Tigecycline treatment causes a decrease in fibrinogen levels","volume":"59","author":"Zhang","year":"2015","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/74\/12\/3423\/30795302\/dkz337.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/74\/12\/3423\/30795302\/dkz337.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,24]],"date-time":"2022-09-24T09:04:10Z","timestamp":1664010250000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/74\/12\/3423\/5543463"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,3]]},"references-count":42,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2019,8,3]]},"published-print":{"date-parts":[[2019,12,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkz337","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,12]]},"published":{"date-parts":[[2019,8,3]]}}}